{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:33:35Z","timestamp":1790638415254,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10067-022-06450-2","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:03:11Z","timestamp":1668621791000},"page":"1019-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-1228","authenticated-orcid":false,"given":"Chi Chiu","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-327X","authenticated-orcid":false,"given":"Ling Yin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-1015","authenticated-orcid":false,"given":"Sau Mei","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-9566","authenticated-orcid":false,"given":"Kar Li","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-4332","authenticated-orcid":false,"given":"Chi Hung","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"6450_CR1","doi-asserted-by":"publisher","first-page":"k5095","DOI":"10.1136\/bmj.k5095","volume":"364","author":"P Le","year":"2019","unstructured":"Le P, Rothberg M (2019) Herpes zoster infection. BMJ 364:k5095","journal-title":"BMJ"},{"key":"6450_CR2","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/14656566.2017.1392508","volume":"18","author":"J Schutzer-Weissmann","year":"2017","unstructured":"Schutzer-Weissmann J, Farquhar-Smith P (2017) Post-herpetic neuralgia - a review of current management and future directions. Expert Opin Pharmacother 18:1739\u20131750","journal-title":"Expert Opin Pharmacother"},{"key":"6450_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, Lepl\u00e8ge A, Schmader KE, Weinke T (2010) The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 8:37","journal-title":"BMC Med"},{"key":"6450_CR4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP (2017) Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 92:1806\u20131821","journal-title":"Mayo Clin Proc"},{"key":"6450_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","volume":"167","author":"M Mareque","year":"2019","unstructured":"Mareque M, Oyag\u00fcez I, Morano R, Casado MA (2019) Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health 167:136\u2013146","journal-title":"Public Health"},{"key":"6450_CR6","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/keaa636","volume":"60","author":"HJ Ryu","year":"2021","unstructured":"Ryu HJ, Han JO, Lee SA, Seo MR, Choi HJ, Ko KP et al (2021) Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea. Rheumatol (Oxford) 60:2427\u20132433","journal-title":"Rheumatol (Oxford)"},{"key":"6450_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Sch\u00e4fer M et al (2022) Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81:41\u201347","journal-title":"Ann Rheum Dis"},{"key":"6450_CR8","doi-asserted-by":"publisher","first-page":"e014032","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Liu HJ, Chen DY (2017) Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open 7:e014032","journal-title":"BMJ Open"},{"key":"6450_CR9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.22628","volume":"67","author":"DA Pappas","year":"2015","unstructured":"Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D et al (2015) Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 67:1671\u20131678","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6450_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","volume":"45","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Michaud K, Chakravarty EF (2006) Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatol (Oxford) 45:1370\u20131375","journal-title":"Rheumatol (Oxford)"},{"key":"6450_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00296-021-04889-1","volume":"41","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Kimura E, Oryoji K, Mizuki SI, Kobayashi T, Nishikawa A et al (2021) Hypertension and dyslipidemia are risk factors for herpes zoster in patients with rheumatoid arthritis: a retrospective analysis using a medical information database. Rheumatol Int 41:1633\u20131639","journal-title":"Rheumatol Int"},{"key":"6450_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R et al (2020) Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 79:1290\u20131297","journal-title":"Ann Rheum Dis"},{"key":"6450_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS et al (2022) Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis 81:206\u2013213","journal-title":"Ann Rheum Dis"},{"key":"6450_CR14","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.3390\/ijms23073636","volume":"23","author":"A Buonacera","year":"2022","unstructured":"Buonacera A, Stancanelli B, Colaci M, Malatino L (2022) Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 23:3636","journal-title":"Int J Mol Sci"},{"key":"6450_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41598-020-79431-7","volume":"11","author":"M Song","year":"2021","unstructured":"Song M, Graubard BI, Rabkin CS, Engels EA (2021) Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep 11:464","journal-title":"Sci Rep"},{"key":"6450_CR16","doi-asserted-by":"publisher","first-page":"e23000","DOI":"10.1002\/jcla.23000","volume":"33","author":"JY Jung","year":"2019","unstructured":"Jung JY, Lee E, Suh CH, Kim HA (2019) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal 33:e23000","journal-title":"J Clin Lab Anal"},{"key":"6450_CR17","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/1756-185X.13157","volume":"20","author":"S Chandrashekara","year":"2017","unstructured":"Chandrashekara S, Mukhtar Ahmad M, Renuka P, Anupama KR, Renuka K (2017) Characterization of neutrophil-to-lymphocyte ratio as a measure of inflammation in rheumatoid arthritis. Int J Rheum Dis 20:1457\u20131467","journal-title":"Int J Rheum Dis"},{"key":"6450_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jcla.21908","volume":"30","author":"R Mercan","year":"2016","unstructured":"Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA et al (2016) The association between neutrophil\/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal 30:597\u2013601","journal-title":"J Clin Lab Anal"},{"key":"6450_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10067-015-2907-0","volume":"35","author":"M Yuksel","year":"2016","unstructured":"Yuksel M, Yildiz A, Oylumlu M, Turkcu FM, Bilik MZ, Ekinci A et al (2016) Novel markers of endothelial dysfunction and inflammation in Beh\u00e7et\u2019s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clin Rheumatol 35:701\u2013708","journal-title":"Clin Rheumatol"},{"key":"6450_CR20","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.21037\/apm-21-1043","volume":"10","author":"K Zhang","year":"2021","unstructured":"Zhang K, Li W, He C, He X, Hou J (2021) The ratio of neutrophil to lymphocyte predicts interstitial lung disease and its prognosis in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective analysis. Ann Palliat Med 10:6493\u20136501","journal-title":"Ann Palliat Med"},{"key":"6450_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","volume":"39","author":"HN Lee","year":"2019","unstructured":"Lee HN, Kim YK, Kim GT, Ahn E, So MW, Sohn DH et al (2019) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-\u03b1 agents in patients with rheumatoid arthritis: a retrospective chart review analysis. Rheumatol Int 39:859\u2013868","journal-title":"Rheumatol Int"},{"key":"6450_CR22","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/1756-185X.13400","volume":"21","author":"G Sargin","year":"2018","unstructured":"Sargin G, Senturk T, Yavasoglu I, Kose R (2018) Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab. Int J Rheum Dis 21:2122\u20132127","journal-title":"Int J Rheum Dis"},{"key":"6450_CR23","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S2665-9913(21)00009-6","volume":"3","author":"CC Mok","year":"2021","unstructured":"Mok CC, Hamijoyo L, Kasitanon N, Chen DY, Chen S, Yamaoka K et al (2021) The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatol 3:e517\u2013e531","journal-title":"Lancet Rheumatol"},{"key":"6450_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713\u2013723","journal-title":"Ann Rheum Dis"},{"key":"6450_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/07853890.2020.1839959","volume":"53","author":"P Bansal","year":"2021","unstructured":"Bansal P, Goyal A, Cusick A, Lahan S, Dhaliwal HS, Bhyan P et al (2021) Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med 53:117\u2013134","journal-title":"Ann Med"},{"key":"6450_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0961203312470186","volume":"22","author":"EF Chakravarty","year":"2013","unstructured":"Chakravarty EF, Michaud K, Katz R, Wolfe F (2013) Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 22:238\u2013244","journal-title":"Lupus"},{"key":"6450_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/ard.49.8.630","volume":"49","author":"K Nagasawa","year":"1990","unstructured":"Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H (1990) High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 49:630\u2013633","journal-title":"Ann Rheum Dis"},{"key":"6450_CR28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1590\/S1807-59322011000700009","volume":"66","author":"HH Chen","year":"2011","unstructured":"Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY (2011) Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo) 66:1177\u20131182","journal-title":"Clinics (Sao Paulo)"},{"key":"6450_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RHU.0b013e3181d52ed7","volume":"16","author":"EF Borba","year":"2010","unstructured":"Borba EF, Ribeiro ACM, Martin P, Costa LP, Guedes LKN, Bonf\u00e1 E (2010) Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol 16:119\u2013122","journal-title":"J Clin Rheumatol"},{"key":"6450_CR30","first-page":"84","volume":"21","author":"LE Kahl","year":"1994","unstructured":"Kahl LE (1994) Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 21:84\u201386","journal-title":"J Rheumatol"},{"key":"6450_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","volume":"39","author":"A Hata","year":"2011","unstructured":"Hata A, Kuniyoshi M, Ohkusa Y (2011) Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 39:537\u2013544","journal-title":"Infection"},{"key":"6450_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2340\/00015555-1454","volume":"93","author":"SCS Hu","year":"2013","unstructured":"Hu SCS, Lin CL, Lu YW, Chen GS, Yu HS, Wu CS et al (2013) Lymphopaenia, anti-Ro\/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. Acta Derm Venereol 93:314\u2013318","journal-title":"Acta Derm Venereol"},{"key":"6450_CR33","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW et al (2016) Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 68:2328\u20132337","journal-title":"Arthritis Rheumatol"},{"key":"6450_CR34","first-page":"6222","volume":"14","author":"D Chen","year":"2017","unstructured":"Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X (2017) Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors. Exp Ther Med 14:6222\u20136228","journal-title":"Exp Ther Med"},{"key":"6450_CR35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0961203320923739","volume":"29","author":"CC Mok","year":"2020","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY (2020) Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus 29:836\u2013844","journal-title":"Lupus"},{"key":"6450_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12939-019-1052-9","volume":"18","author":"JYM Siu","year":"2019","unstructured":"Siu JYM, Fung TKF, Leung LHM (2019) Social and cultural construction processes involved in HPV vaccine hesitancy among Chinese women: a qualitative study. Int J Equity Health 18:147","journal-title":"Int J Equity Health"},{"key":"6450_CR37","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1016\/j.vaccine.2020.08.038","volume":"38","author":"LHW Lau","year":"2020","unstructured":"Lau LHW, Lee SS, Wong NS (2020) The continuum of influenza vaccine hesitancy among nursing professionals in Hong Kong. Vaccine 38:6785\u20136793","journal-title":"Vaccine"},{"key":"6450_CR38","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1016\/j.vaccine.2021.05.036","volume":"39","author":"TT Luk","year":"2021","unstructured":"Luk TT, Zhao S, Wu Y, Wong JYH, Wang MP, Lam TH (2021) Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: a population-based survey. Vaccine 39:3602\u20133607","journal-title":"Vaccine"},{"key":"6450_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/21645515.2018.1514228","volume":"15","author":"CC Mok","year":"2019","unstructured":"Mok CC (2019) Herpes zoster vaccination in systemic lupus erythematosus: the current status. Hum Vaccin Immunother 15:45\u201348","journal-title":"Hum Vaccin Immunother"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06450-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:30:38Z","timestamp":1679873438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06450-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6450"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06450-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}